Symbols / GNTA Stock $0.61 -2.65% Genenta Science S.p.A.

Healthcare • Biotechnology • Italy • NCM
GNTA (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Pierluigi Paracchi
Exch · Country NCM · Italy
Market Cap 14.46M
Enterprise Value -6.08M
Income -6.53M
Sales —
FCF (ttm) -3.10M
Book/sh 1.09
Cash/sh 1.19
Employees 9
Insider 10d —
IPO Dec 15, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -0.94
PEG —
P/S —
P/B 0.56
P/C —
EV/EBITDA 0.93
EV/Sales —
Quick Ratio 13.90
Current Ratio 14.15
Debt/Eq 34.81
LT Debt/Eq —
EPS (ttm) -0.39
EPS next Y -0.65
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) —
Earnings (prior) —
ROA -17.67%
ROE -38.03%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 23.59M
Shs Float 13.87M
Insider Own 44.60%
Instit Own 14.31%
Short Float 0.06%
Short Ratio 0.29
Short Interest 13.32K
52W High 10.00
vs 52W High -93.87%
52W Low 0.59
vs 52W Low 3.90%
Beta 0.73
Impl. Vol. —
Rel Volume 0.32
Avg Volume 75.82K
Volume 24.40K
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $0.63
Price $0.61
Change -2.65%
About

Genenta Science S.p.A., a clinical-stage biotechnology company, develops hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company offers Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is developing Temferon for use in the treatment of other solid tumor indications. In addition, the company develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$0.61
Latest analyst target
3. DCF / Fair value
$-2.36
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.61
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2024-10-02 reit HC Wainwright & Co. Buy → Buy $25
2024-05-13 reit HC Wainwright & Co. Buy → Buy $25
2023-02-08 reit HC Wainwright & Co. — → Buy $25
2023-01-05 init EF Hutton — → Buy $15
2022-07-25 init HC Wainwright & Co. — → Buy $25
2022-01-13 init Maxim Group — → Buy $21
News
RSS: Latest GNTA news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
6.60
-32.37%
9.76
-16.78%
11.73
+6.24%
11.04
Research And Development
2.70
-43.91%
4.81
-25.66%
6.47
+21.27%
5.34
Selling General And Administration
3.90
-21.15%
4.95
-5.84%
5.26
-7.83%
5.71
General And Administrative Expense
3.90
-21.15%
4.95
-5.84%
5.26
-7.83%
5.71
Salaries And Wages
1.98
-20.03%
2.48
-2.25%
2.54
-1.07%
2.56
Other Gand A
1.90
-22.54%
2.45
-9.12%
2.70
+43.25%
1.89
Other Operating Expenses
—
—
—
—
Total Expenses
6.60
-32.37%
9.76
-16.78%
11.73
+6.24%
11.04
Operating Income
-6.60
+32.37%
-9.76
+16.78%
-11.73
-6.24%
-11.04
Total Operating Income As Reported
-6.60
+32.37%
-9.76
+16.78%
-11.73
-6.24%
-11.04
EBITDA
-6.58
+32.35%
-9.72
+16.86%
-11.69
-5.91%
-11.04
Normalized EBITDA
-6.03
+39.47%
-9.96
+13.19%
-11.47
+13.89%
-13.32
Reconciled Depreciation
0.03
-36.93%
0.04
+4.88%
0.04
+591.42%
0.01
EBIT
-6.60
+32.37%
-9.76
+16.78%
-11.73
-6.24%
-11.04
Total Unusual Items
-0.55
-326.58%
0.24
+211.11%
-0.22
-109.48%
2.29
Total Unusual Items Excluding Goodwill
-0.55
-326.58%
0.24
+211.11%
-0.22
-109.48%
2.29
Net Income
-6.53
+26.73%
-8.91
+23.47%
-11.65
-37.36%
-8.48
Pretax Income
-6.53
+26.73%
-8.91
+23.47%
-11.65
-37.36%
-8.48
Net Non Operating Interest Income Expense
0.61
+649.95%
0.08
-73.76%
0.31
+736.16%
0.04
Interest Expense Non Operating
—
—
—
—
Net Interest Income
0.61
+649.95%
0.08
-73.76%
0.31
+736.16%
0.04
Interest Expense
—
—
—
—
Interest Income Non Operating
0.61
+649.95%
0.08
-73.76%
0.31
+736.16%
0.04
Interest Income
0.61
+649.95%
0.08
-73.76%
0.31
+736.16%
0.04
Other Income Expense
-0.53
-169.37%
0.77
+447.52%
-0.22
-108.77%
2.53
Other Non Operating Income Expenses
0.01
-97.84%
0.53
+10965.29%
-0.00
-102.01%
0.24
Gain On Sale Of Security
-0.55
-326.58%
0.24
+211.11%
-0.22
-109.48%
2.29
Tax Provision
0.00
0.00
0.00
0.00
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-6.53
+26.73%
-8.91
+23.47%
-11.65
-37.36%
-8.48
Net Income From Continuing Operation Net Minority Interest
-6.53
+26.73%
-8.91
+23.47%
-11.65
-37.36%
-8.48
Net Income From Continuing And Discontinued Operation
-6.53
+26.73%
-8.91
+23.47%
-11.65
-37.36%
-8.48
Net Income Continuous Operations
-6.53
+26.73%
-8.91
+23.47%
-11.65
-37.36%
-8.48
Normalized Income
-5.98
+34.63%
-9.15
+19.91%
-11.43
-6.17%
-10.76
Net Income Common Stockholders
-6.53
+26.73%
-8.91
+23.47%
-11.65
-37.36%
-8.48
Diluted EPS
-0.33
+32.65%
-0.49
+23.44%
-0.64
-36.17%
-0.47
Basic EPS
-0.33
+32.65%
-0.49
+23.44%
-0.64
-36.17%
-0.47
Basic Average Shares
19.71
+7.86%
18.27
+0.31%
18.22
+0.00%
18.22
Diluted Average Shares
19.71
+7.86%
18.27
+0.31%
18.22
+0.00%
18.22
Diluted NI Availto Com Stockholders
-6.53
+26.73%
-8.91
+23.47%
-11.65
-37.36%
-8.48
Insurance And Claims
0.02
+14.73%
0.02
-17.20%
0.02
-98.26%
1.26
Total Other Finance Cost
—
—
-0.31
-736.16%
-0.04
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
31.89
+115.12%
14.82
-33.66%
22.35
-33.17%
33.44
Current Assets
29.98
+107.14%
14.47
-31.91%
21.26
-32.99%
31.72
Cash Cash Equivalents And Short Term Investments
28.15
+122.35%
12.66
-32.57%
18.78
-36.98%
29.79
Cash And Cash Equivalents
5.53
+20.65%
4.58
+24.12%
3.69
-87.61%
29.79
Cash Financial
5.53
+20.65%
4.58
+24.12%
3.69
-87.61%
29.79
Other Short Term Investments
22.62
+180.04%
8.08
-46.45%
15.08
0.00
Receivables
1.29
-11.24%
1.45
-27.71%
2.00
+28.24%
1.56
Taxes Receivable
1.29
-11.24%
1.45
-27.71%
2.00
+28.24%
1.56
Prepaid Assets
0.21
+34.62%
0.15
-62.65%
0.41
+184.93%
0.14
Current Deferred Assets
—
—
—
—
Other Current Assets
0.34
+60.05%
0.21
+226.04%
0.06
-70.53%
0.22
Total Non Current Assets
1.91
+444.07%
0.35
-67.82%
1.09
-36.45%
1.72
Net PPE
0.02
-47.66%
0.04
-48.27%
0.08
-25.67%
0.11
Gross PPE
0.15
+5.40%
0.14
+3.27%
0.14
+10.50%
0.12
Accumulated Depreciation
-0.13
-28.56%
-0.10
-82.76%
-0.05
-343.01%
-0.01
Machinery Furniture Equipment
0.09
+0.00%
0.09
+0.00%
0.09
-29.07%
0.12
Other Properties
0.06
+14.27%
0.05
+9.12%
0.05
—
Non Current Accounts Receivable
1.88
+548.90%
0.29
-63.61%
0.80
-48.97%
1.56
Other Non Current Assets
0.00
-74.88%
0.02
-91.48%
0.21
+396.28%
0.04
Total Liabilities Net Minority Interest
10.05
+331.59%
2.33
+21.59%
1.91
-16.73%
2.30
Current Liabilities
2.12
+0.88%
2.10
+20.96%
1.74
-20.51%
2.18
Payables And Accrued Expenses
2.00
+13.47%
1.76
+18.98%
1.48
-21.48%
1.89
Payables
1.81
+263.41%
0.50
+6.89%
0.47
-60.98%
1.19
Accounts Payable
1.51
+374.87%
0.32
+7.75%
0.29
-71.69%
1.04
Current Accrued Expenses
0.19
-85.02%
1.26
+24.53%
1.01
+46.72%
0.69
Employee Benefits
0.33
+43.91%
0.23
+38.33%
0.16
+85.08%
0.09
Other Current Liabilities
0.12
-64.77%
0.34
+32.42%
0.26
-14.37%
0.30
Total Non Current Liabilities Net Minority Interest
7.93
+3364.36%
0.23
+27.71%
0.18
+54.28%
0.12
Long Term Debt And Capital Lease Obligation
7.60
—
—
—
Long Term Debt
7.60
—
—
—
Non Current Pension And Other Postretirement Benefit Plans
0.33
+43.91%
0.23
+38.33%
0.16
+85.08%
0.09
Other Non Current Liabilities
—
0.00
-92.07%
0.01
-46.38%
0.03
Stockholders Equity
21.84
+74.79%
12.50
-38.84%
20.43
-34.38%
31.14
Common Stock Equity
21.84
+74.79%
12.50
-38.84%
20.43
-34.38%
31.14
Capital Stock
84.26
+23.07%
68.46
+1.66%
67.34
+1.11%
66.60
Common Stock
84.26
+23.07%
68.46
+1.66%
67.34
+1.11%
66.60
Share Issued
23.43
+28.12%
18.29
+0.40%
18.22
+0.00%
18.22
Ordinary Shares Number
23.43
+28.12%
18.29
+0.40%
18.22
+0.00%
18.22
Additional Paid In Capital
—
—
0.00
0.00
Retained Earnings
-62.59
-11.65%
-56.06
-18.91%
-47.14
-32.93%
-35.47
Gains Losses Not Affecting Retained Earnings
0.17
+87.20%
0.09
-61.52%
0.23
0.00
Other Equity Adjustments
0.17
+87.20%
0.09
-61.52%
0.23
—
Total Equity Gross Minority Interest
21.84
+74.79%
12.50
-38.84%
20.43
-34.38%
31.14
Total Capitalization
29.44
+135.63%
12.50
-38.84%
20.43
-34.38%
31.14
Working Capital
27.86
+125.17%
12.37
-36.61%
19.52
-33.91%
29.54
Invested Capital
29.44
+135.63%
12.50
-38.84%
20.43
-34.38%
31.14
Total Debt
7.60
—
—
—
Net Debt
2.08
—
—
—
Net Tangible Assets
21.84
+74.79%
12.50
-38.84%
20.43
-34.38%
31.14
Tangible Book Value
21.84
+74.79%
12.50
-38.84%
20.43
-34.38%
31.14
Dueto Related Parties Current
0.30
+66.74%
0.18
+5.40%
0.17
+12.44%
0.15
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-6.87
-10.06%
-6.24
+44.31%
-11.21
-51.05%
-7.42
Cash Flow From Continuing Operating Activities
-6.87
-10.06%
-6.24
+44.31%
-11.21
-51.05%
-7.42
Net Income From Continuing Operations
-6.53
+26.73%
-8.91
+23.47%
-11.65
-37.36%
-8.48
Depreciation Amortization Depletion
0.03
-36.93%
0.04
+4.88%
0.04
+591.42%
0.01
Depreciation
0.03
-36.93%
0.04
+4.88%
0.04
+591.42%
0.01
Depreciation And Amortization
0.03
-36.93%
0.04
+4.88%
0.04
+591.42%
0.01
Other Non Cash Items
—
—
—
0.03
Pension And Employee Benefit Expense
0.10
+58.48%
0.06
-16.62%
0.08
+29.73%
0.06
Stock Based Compensation
1.01
+19.18%
0.85
+14.51%
0.74
+2.37%
0.72
Operating Gains Losses
0.10
+58.48%
0.06
-16.62%
0.08
-16.23%
0.09
Unrealized Gain Loss On Investment Securities
0.10
0.00
0.00
—
Net Foreign Currency Exchange Gain Loss
—
0.00
0.00
-100.00%
0.03
Change In Working Capital
-1.58
-191.94%
1.72
+511.27%
-0.42
-273.78%
0.24
Change In Prepaid Assets
-0.02
-102.57%
0.67
+220.45%
-0.55
-35.96%
-0.41
Change In Payables And Accrued Expense
0.24
-15.56%
0.28
+169.38%
-0.41
-147.58%
0.85
Change In Accrued Expense
-1.07
-531.58%
0.25
-22.96%
0.32
+311.38%
-0.15
Change In Payable
1.31
+3988.30%
0.03
+104.41%
-0.73
-172.52%
1.00
Change In Account Payable
1.31
+3988.30%
0.03
+104.41%
-0.73
-172.52%
1.00
Change In Other Current Assets
-1.58
-325.66%
0.70
+17.23%
0.60
+239.50%
-0.43
Change In Other Current Liabilities
-0.22
-417.50%
0.07
+224.95%
-0.06
-124.71%
0.22
Investing Cash Flow
-14.54
-311.30%
6.88
+146.22%
-14.89
-54915.39%
-0.03
Cash Flow From Continuing Investing Activities
-14.54
-311.30%
6.88
+146.22%
-14.89
-54915.39%
-0.03
Net PPE Purchase And Sale
-0.01
-70.66%
-0.00
+67.60%
-0.01
+49.05%
-0.03
Purchase Of PPE
-0.01
-70.66%
-0.00
+67.60%
-0.01
+49.05%
-0.03
Capital Expenditure
-0.01
-70.66%
-0.00
+67.60%
-0.01
+49.05%
-0.03
Net Investment Purchase And Sale
-14.54
-311.05%
6.89
+146.29%
-14.88
0.00
Purchase Of Investment
-33.17
-102.47%
-16.38
-10.09%
-14.88
0.00
Sale Of Investment
18.63
-19.94%
23.27
0.00
0.00
Financing Cash Flow
22.29
+8127.65%
0.27
+50914.12%
0.00
0.00
Cash Flow From Continuing Financing Activities
22.29
+8127.65%
0.27
+50914.12%
0.00
0.00
Net Issuance Payments Of Debt
7.50
0.00
0.00
—
Issuance Of Debt
7.50
0.00
0.00
—
Long Term Debt Issuance
7.50
0.00
0.00
—
Net Long Term Debt Issuance
7.50
0.00
0.00
—
Net Common Stock Issuance
—
—
0.00
0.00
Proceeds From Stock Option Exercised
—
—
0.00
0.00
Net Other Financing Charges
14.79
+5358.94%
0.27
+50914.12%
0.00
—
Changes In Cash
0.88
-4.18%
0.91
+103.50%
-26.10
-250.52%
-7.45
Effect Of Exchange Rate Changes
0.07
+400.09%
-0.02
-273.46%
-0.01
0.00
Beginning Cash Position
4.58
+24.12%
3.69
-87.61%
29.79
-19.99%
37.24
End Cash Position
5.53
+20.65%
4.58
+24.12%
3.69
-87.61%
29.79
Free Cash Flow
-6.88
-10.10%
-6.24
+44.34%
-11.22
-50.68%
-7.45
Common Stock Issuance
—
—
0.00
0.00
Issuance Of Capital Stock
—
—
0.00
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category